

# Max Meyrath

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1717774/publications.pdf>

Version: 2024-02-01

9  
papers

244  
citations

1478505

6  
h-index

1588992

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atypical opioid receptors: unconventional biology and therapeutic opportunities. , 2022, 233, 108014.		15
2	Nanoluciferase-based methods to monitor activation, modulation and trafficking of atypical chemokine receptors. <i>Methods in Cell Biology</i> , 2022, , 279-294.	1.1	9
3	The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
4	Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 813-823.	4.9	15
5	The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 209.	17.1	17
6	The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. <i>Nature Communications</i> , 2020, 11, 3033.	12.8	74
7	The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy. <i>Advances in Cancer Research</i> , 2020, 145, 99-138.	5.0	23
8	Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. <i>British Journal of Pharmacology</i> , 2018, 175, 1419-1438.	5.4	52
9	Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists. <i>Biochemical Pharmacology</i> , 2018, 153, 299-309.	4.4	33